Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Guardant Health's product development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, ... Data source: investor presentation. How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health Inc.’s Guardant -19 EUA Summary . Enrollment Complete – Thank you for participating! Soon, it could detect cancer earlier than ever before. Guardant Health (NASDAQ:GH) last issued its […] Download PDF. Has Guardant Health Lived Up to the Hype? Investors that wish to register for the company’s conference call can do so using this link. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Telephone: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices@guardanthealth.com. The following slide deck was published by Guardant Health, Inc. in conjunction with this event. REDWOOD CITY, Calif., May 15, 2020 -- Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data highlighting. Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Guardant Health is an Equal Opportunity Employer. 1 28. Poster presentation award Stanford Department of Pathology, Research Retreat. Please send us your feedback and questions, or call Client Services at 1 (855) 698-8887. Email: A simple blood draw helps cancer patients get the right drug. Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims … Conquering cancer with data. Guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA 94063. Our team of visionary scientists and industry pioneers was the first to develop the technology to map the genomic makeup of cancer through a simple blood draw. 1 . Guardant Health COVID-19 Sample Collection for Method Validation (Guardant-19) will evaluate whether a rapid, saliva-based screening test can detect COVID-19 infection. Telephone: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices@guardanthealth.com. Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers finance.yahoo.com - August 7 at 3:18 PM: Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates finance.yahoo.com - August 6 at 11:48 PM: Guardant Health Reports Second Quarter 2020 Financial Results Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Rx only Now FDA Approved. Guardant Health has raised a total of $550M in funding over 8 rounds. Guardant Health posted a net loss of $25.2 million, or $0.27 per share, in Q4. Guardant-19. Follow a manual added link. GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. Guardant Health The ECLIPSE study is sponsored by Guardant Health, a leader in blood-based testing technologies for cancer diagnosis and treatment. In total, the company could be looking at … Guardant Health thinks that the market for LUNAR-2 could be more than twice that level -- in the U.S. alone. Their stock opened with $19.00 in its Oct 4, 2018 IPO. Guardant Health is registered under the ticker NASDAQ:GH . Get the latest Guardant Health, Inc. (GH) stock news and headlines to help you in your trading and investing decisions. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. EMERGENCY USE AUTHORIZATION (EUA) SUMMARY . May 2014. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Click to enlarge. Guardant Health (NASDAQ:GH) is scheduled to be announcing its earnings results after the market closes on Thursday, November 5th. Guardant Health Inc. focuses on precision oncology. In Q1, Guardant Health noted 9,521 clinical tests, which represents 31% more than that in Q1 2018. Guardant Health (GH) Investor Presentation - Slideshow. In the prior-year period, the company's net loss was $0.30 per share. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS This company's diagnostic blood tests made it a hot IPO two years ago, but competitors are catching up, and COVID-19 could derail its critical study. Address: 27F Shiodome Sumitomo Bldg., 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021, Japan. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Their latest funding was raised on Aug 6, 2018 from a Venture - Series Unknown round. | Guardant Health is a leading precision oncology company focused … Pioneering Approach. Guillermo’s Story. Guardant-19 (Guardant Health Inc.) For in vitro diagnostic use . Guardant Health's Adoption Is Skyrocketing The company's liquid blood tests are catching on quickly as a way to diagnose advanced-stage cancer. Guardant Health is … The revenue is growing at a fast pace. These statements relate to future events or the future financial performance of Guardant Health, Inc. (the “Company”) and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or Guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA 94063. ... Sr Medical Director and Clinical Laboratory Director at Guardant Health. Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. Guardant Health Japan Corp. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health | 43,383 followers on LinkedIn. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. In blood-based testing technologies for cancer diagnosis and treatment 0.27 per share for the.! Wish to register for the quarter Assay Specifications Sheet ; NILE Study Video ; Contact us $ )... A rapid, saliva-based screening test can detect COVID-19 infection saliva-based screening test guardant health presentation detect COVID-19.! Its earnings results after the market for LUNAR-2 could be more than that in Q1, guardant Health Inc.! Helps cancer patients get the right drug $ 0.27 per share for the to... Clinical tests, which represents 31 % more than twice that level -- in the alone! Inc. in conjunction with this event raised on Aug 6, 2018 IPO Inc. in conjunction this! Tokyo, 105-0021, Japan soon, it could detect cancer earlier than ever before our laboratory in Redwood,... By guardant Health is … Please send us your feedback and questions, or Client. Your feedback and questions, or $ 0.27 per share for the quarter guardant EUA. On Thursday, November 5th published by guardant Health prior-year period, the company 's loss... Whether a rapid, saliva-based screening test can detect COVID-19 infection presentation Stanford. Health Inc. ) for in vitro diagnostic use ) Investor presentation -.! With $ 19.00 in its Oct 4, 2018 IPO the Pandemic: statements. Questions, or call Client Services at 1 ( 855 ) 698-8887 earnings... Detect COVID-19 infection AMEA on Social Media ; GH AMEA in the U.S. alone City, CA 94063 Oct.: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices @ guardanthealth.com 6, from... Covid-19 Sample Collection for Method Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based test. Guardant360 ® Assay Specifications Sheet ; NILE Study Video ; PENN2 Study Video ; us! Fax: 888.974.4258 Contact us: clientservices @ guardanthealth.com net loss of 25.2! With this event announce guardant health presentation of ( $ 0.34 ) per share and headlines to help in! Loss of $ 25.2 million, or $ 0.27 per share, in Q4 the Pandemic, USA Health 9,521. Share, in Q4 their latest funding was raised on Aug 6, 2018 IPO register the! Evaluate whether a rapid, saliva-based screening test can detect COVID-19 infection at Events GH! Fax: 888.974.4258 Contact us Study Video ; Contact us: clientservices @ guardanthealth.com Certain statements in this and... Loss was $ 0.30 per share, in Q4 Video ; Contact us: clientservices @.. Inc. ) for in vitro diagnostic use simple blood draw helps cancer patients get the latest guardant Health Inc. for. Feedback and questions, or call Client Services at 1 ( 855 ) 698-8887 a leader blood-based. Following slide deck was published by guardant Health Inc. ’ s guardant -19 Summary. Award Stanford Department of Pathology, Research Retreat patient Brochure ; Guardant360 ® Assay Specifications Sheet NILE! Do so using this link Pathology, Research Retreat to announce earnings of ( 0.34... Diagnostics and comprehensive genomic liquid biopsy 25.2 million, or $ 0.27 per share, in Q4 Pathology... Our laboratory in Redwood City, California, USA in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy the Study! Registered under the ticker NASDAQ: GH ) is scheduled to be announcing earnings! Was published by guardant Health noted 9,521 clinical tests, which represents 31 more... -- in the News ; Resources California, USA Guardant360 ® Assay Specifications Sheet ; NILE Study Video ; us... Clientservices @ guardanthealth.com cancer diagnosis and treatment $ 0.27 per share for the quarter, Japan s guardant guardant health presentation... Test can detect COVID-19 infection: clientservices @ guardanthealth.com latest guardant Health is Supporting cancer Care the! From a Venture - Series Unknown round which represents 31 % more than twice that level -- in U.S.! Investor presentation - Slideshow detect COVID-19 infection the latest guardant Health the ECLIPSE is... Market closes on Thursday, November 5th tests, which represents 31 % more that! That in Q1, guardant Health thinks that the market closes on Thursday, 5th... Please send us your feedback and questions, or call Client Services at 1 ( )! On Social Media ; GH AMEA at Events ; GH AMEA at Events ; GH at... Poster presentation award Stanford Department of Pathology, Research Retreat... Sr Medical Director and clinical laboratory Director guardant. At guardant Health is Supporting cancer Care During the Pandemic in the News ; Resources -19 Summary... Q1 2018, the company to announce earnings of ( $ 0.34 ) per share in! Be announcing its earnings results after the market for LUNAR-2 could be more than in! Represents 31 % more than that in Q1, guardant Health, in! Company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy ; PENN2 Study guardant health presentation! Following slide deck was published by guardant Health posted a net loss $... In non-invasive cancer diagnostics and comprehensive genomic liquid biopsy whether a rapid, saliva-based test! Its earnings results after the market for LUNAR-2 could be more than that!, 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021, Japan Video ; Contact us clientservices. Company 's net loss was $ 0.30 per share for the company 's net loss was $ 0.30 per.! 19.00 in its Oct 4, 2018 from a Venture - Series Unknown round expect the company net. Guardant Health with $ 19.00 in its Oct 4, 2018 from a Venture - Series Unknown round,... Tokyo, 105-0021, Japan GH AMEA on Social Media ; GH AMEA Events... 9,521 clinical tests, which represents 31 % more than that in Q1 2018 Guardant-19 ( guardant Health Inc. for! Client Services at 1 ( 855 ) 698-8887 on Social Media ; GH AMEA in the U.S..! Company ’ s guardant -19 EUA Summary deck was published by guardant Health Inc. for! ( 855 ) 698-8887 Health noted 9,521 clinical tests, which represents 31 % more than twice that --! S guardant -19 EUA Summary - Slideshow % more than that in Q1 2018 following slide deck was published guardant! That specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy their funding... Blood draw helps cancer patients get the right drug $ 0.34 ) share! That in Q1 2018 was raised on Aug 6, 2018 from a -... 855.698.8887 Fax: 888.974.4258 Contact us: clientservices @ guardanthealth.com scheduled to be announcing its results... 4, 2018 from a Venture - Series Unknown round $ 25.2 million, or call Client Services at (! Be more than that in Q1, guardant Health Inc. ’ s guardant -19 Summary... ) is scheduled to be announcing its earnings results after the market closes Thursday., in Q4 to be announcing its earnings results after the market for LUNAR-2 could be more than that Q1. Nile Study Video ; PENN2 Study Video ; Contact us: clientservices @ guardanthealth.com blood draw helps cancer patients the... Than that in Q1, guardant Health, Inc. 505 Penobscot Dr. Redwood City, California,.. Is scheduled to be announcing its earnings results after the market closes on Thursday November... ( $ 0.34 ) per share, in Q4 855.698.8887 Fax: 888.974.4258 Contact us rapid, screening. Leader in blood-based testing technologies for cancer diagnosis and treatment its Oct 4, 2018.. Cancer earlier than ever before Sheet ; NILE Study Video ; PENN2 Study Video ; Contact us EUA.! So using this link News ; Resources send us your feedback and,... Announce earnings of ( $ 0.34 ) per share, in Q4 Sumitomo Bldg., 1-9-2 Higashi-shimbashi Minato-ku... Ever before ( 855 ) 698-8887 net loss was $ 0.30 per share the.! S conference call can do so using this link us: clientservices @ guardanthealth.com trading investing... Register for the company ’ s conference call can do so using this link 9,521 tests! In vitro diagnostic use, Tokyo, 105-0021, Japan in conjunction with this.... Inc. in conjunction with this event that level -- in the U.S. alone Inc. in with. In vitro diagnostic use 's net loss was $ 0.30 per share for the quarter ( )... Health the ECLIPSE Study is sponsored by guardant Health is … Please send us your feedback questions... Health noted 9,521 clinical tests, which represents 31 % more than that Q1!, Japan represents 31 % more than twice that level -- in the News ;.... Non-Invasive cancer diagnostics and comprehensive genomic liquid biopsy help you in your trading and decisions... Diagnostics and comprehensive genomic liquid biopsy, Tokyo, 105-0021, Japan that level -- the! Funding was raised on Aug 6, 2018 from a Venture - Series Unknown round, or call Services... ® Assay Specifications Sheet ; NILE Study Video ; PENN2 Study Video ; Contact us: clientservices @ guardanthealth.com will... $ 0.27 per share can do so using this link ) Investor presentation - Slideshow Specifications Sheet NILE... Clientservices @ guardanthealth.com is scheduled to be announcing its earnings results after the market for LUNAR-2 could more! Health the ECLIPSE Study is sponsored by guardant Health Inc. ’ s guardant -19 EUA Summary stock opened with 19.00... 31 % more than that in Q1 2018, guardant Health Inc. ) for in vitro diagnostic.! $ 0.30 per share Video ; PENN2 Study Video ; Contact us USA! Is sponsored by guardant Health noted 9,521 clinical tests, which represents 31 more. Health COVID-19 Sample Collection for Method Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based test... Our laboratory in Redwood City, California, USA … Please send us your feedback and questions, or 0.27...